Founded in 1992 in Martinsried near Munich, Germany, MorphoSys AG is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies in the areas of cancer and autoimmune diseases.
MorphoSys is advancing its proprietary pipeline of new drugs based on its leading expertise in antibody and protein technology.
The focus is on therapies in the field of oncology (benign and malignant tumor types as well as cancer). Based on its expertise in antibody, protein and peptide technologies.
Morphosys partner companies include the following international pharmaceutical companies: Bayer Pharma AG, Boehringer Ingelheim, Novartis AG, Johnson & Johnson, Merck & Co., Pfizer, Roche
Latest news: Morphosys announced in mid-October that its licensing partner Roche has received "breakthrough therapy" status for its Alzheimer's drug gantenerumab.
Current share price: € 39.15
Performance 3 years: -49.66
Performance 5 years: -5.33
Do you already know the German company?
---------------
Not an investment recommendation - Source: Wikipedia, deraktionaer
